01—Abstract
Summary
Summary of the 10-K filed February 28, 2011. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation's 2010 10-K filing indicates a strong year of growth, with total net sales increasing by 9.5% to $1.45 billiona.
The company's Heart Valve Therapy segment was a primary driver, showing a 17.3%b increase in net sales, largely due to the success of its transcatheter heart valves and new surgical valve offerings. The Critical Care and Cardiac Surgery Systems segments also saw modest growth. Geographically, international sales showed robust performance, growing by 14.9%, with Europe and Japan being key contributors.
The company continued to invest heavily in research and development, allocating 14.1%c of net sales to fuel innovation in its core product lines and emerging technologies. Financially, Edwards Lifesciences maintained a healthy gross profit margin of 71.8% and managed its selling, general, and administrative expenses effectively, with these expenses as a percentage of net sales decreasing slightly.
The company also initiated a stock repurchase program, demonstrating a commitment to returning value to shareholders. Despite facing a dynamic and competitive market, the company's focus on technological advancement and addressing critical cardiovascular needs positions it for continued growth.
02—Key points
Key Highlights
- Total net sales increased by 9.5% to $1.45 billion in 2010.
- Heart Valve Therapy segment led growth with a 17.3% sales increase, driven by transcatheter valves.
- International sales grew by 14.9%, with Europe and Japan showing strong performance.
- Research and development spending increased to 14.1% of net sales, reflecting a commitment to innovation.
- Gross profit margin improved to 71.8% in 2010.
- The company ended the year with $396.1 million in cash and cash equivalents.
- A stock repurchase program was active, with $398.0 million remaining authorization as of year-end.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 28, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $1.45B$1.32B | +9.5% |
| Cost of Revenue | $408.30M$399.10M | +2.3% |
| Gross Profit | $1.04B$922.30M | +12.6% |
| R&D Expenses | $204.40M$175.50M | +16.5% |
| SG&A Expenses | $550.00M$508.80M | +8.1% |
| Interest Expense | $2.40M$2.70M | −11.1% |
| Net Income | $218.00M$229.10M | −4.8% |
| EPS (Basic) | $0.32$0.34 | −5.9% |
| EPS (Diluted) | $0.30$0.33 | −6.2% |
| Shares Outstanding (Basic) | 682.20M675.00M | +1.1% |
| Shares Outstanding (Diluted) | 715.20M705.00M | +1.4% |
05—Questions
Frequently Asked Questions
What were the primary growth drivers for Edwards Lifesciences in 2010?
The primary growth drivers were the Heart Valve Therapy segment, particularly the sales of transcatheter heart valves like the Edwards SAPIEN XT, and the introduction of new surgical valve products. International sales, especially in Europe and Japan, also contributed significantly to the overall revenue growth.
How did the company manage its expenses in 2010?
Edwards Lifesciences managed its expenses well, with selling, general, and administrative expenses as a percentage of net sales decreasing slightly to 38.0%. The company also maintained a strong gross profit margin of 71.8%, indicating efficient cost management in its operations.
What is the company's strategy regarding innovation and future growth?
The company is heavily invested in research and development, allocating 14.1% of net sales to develop new products and enhance existing ones. Key areas of focus include advancing transcatheter heart valve technologies and developing minimally invasive solutions for critical care and cardiac surgery.
How is the company addressing competition and market dynamics?
Edwards Lifesciences competes by focusing on clinical superiority and innovative features that benefit patients. The company acknowledges the highly competitive nature of the medical device industry and the pressure to demonstrate value and improve clinical outcomes, which it addresses through continuous R&D and strategic product development.
06—Continue